Kelun Pharma’s SKB264 ADC Receives NMPA Green Light for Phase II Solid Tumor Study
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) announced that its antibody drug conjugate (ADC)...
Drug
Luye Pharma Initiates Phase III Study of Trulicity Biosimilar BA5101 in China
China-based Luye Pharma Group (HKG: 2186) announced the initiation of a Phase III clinical study...
Beijing Science Sun’s LZ901 Shingles Vaccine Receives FDA IND Approval
China-based Beijing Science Sun Pharmaceutical Co., Ltd (SHE: 300485) announced that its subsidiary Beijing Luzhu...
BeiGene’s Tislelizumab Faces FDA Delay Due to Inspection Hurdles
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced a delay in the U.S. FDA’s decision...
Frontier Biotech and Asymchem Partner on COVID-19 Drug FB2001 Development
China-based Frontier Biotechnologies Inc. (SHE: 200342) announced a strategic partnership with Asymchem Laboratories (Tianjin) Co.,...
Hangzhou DAC Biotech Doses First Patient in DXC007 AML Study
China-based Hangzhou DAC Biotech Co., Ltd announced the first patient enrollment and dosing in a...
Simcere’s Trilaciclib Wins NMPA Approval for Chemotherapy Myeloprotection
Jiangsu Simcere Pharmaceutical Co., Ltd’s trilaciclib has received marketing approval from the National Medical Products...
Huadong Medicine’s Biosimilar Victoza (Liraglutide) Accepted for NMPA Review
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market filing for a biosimilar...
Zai Lab’s Efgartigimod NDA Accepted by NMPA for Myasthenia Gravis
Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced that the National Medical Products Administration (NMPA)...
Zhejiang Medicine’s ARX305 ADC Receives Clinical Trial Approval for CD70-Positive Cancers
China-based Zhejiang Medicine Co., Ltd (SHA: 600216) announced that its subsidiary NovoCodex Biopharmaceuticals Ltd has...
Abbisko Therapeutics’ ABSK021 Receives BTD for Giant Cell Tumor Treatment
Shanghai-based Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that its Category 1 drug ABSK021 has...
HutchMed’s Orpathys-Tagrisso Combo Shows Promise in NSCLC at WCLC
China-based HutchMed (NASDAQ: HCM, HKG: 0013) announced the publication of an abstract detailing the SAVANNAH...
Junshi Biosciences’ JS203 Bispecific Antibody Receives NMPA Green Light for NHL Study
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that the National Medical Products Administration (NMPA)...
Eli Lilly’s Trulicity + Insulin Combo Meets Goals in China’s AWARD-CHN3 Study
Eli Lilly (NYSE: LLY) announced that its Phase III AWARD-CHN3 study of Trulicity (dulaglutide) combined...
CDE Grants Priority Review to Ascentage’s Olerembatinib and Roche’s Crovalimab
The Center for Drug Evaluation (CDE) has granted priority review status to two drugs: Suzhou...
Hengrui Medicine’s SHR-1701 + Ameile Combo Greenlit for EGFR-Mutated NSCLC Trial
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that the National Medical Products Administration...
Eucure Biopharma Doses First Patient in YH003 + Keytruda Trial for Mucosal Melanoma
Eucure Biopharma, a subsidiary of Sino-US contract research organization Biocytogen, announced that the first patient...
Overland ADCT BioPharma Launches Global Phase III Trial for Zynlonta in DLBCL
Overland ADCT BioPharma, a joint venture between China’s Overland Pharmaceuticals and Switzerland’s ADC Therapeutics SA...
Bio-Thera Solutions Doses First Patient in BAT8006 Phase I Study for Solid Tumors
Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced that the first patient has been dosed in a...
OBI Pharma Halts OBI 888 Trial Over Manufacturing Costs, Shifts Focus to Globo H ADC
Taiwan-based OBI Pharma (TPEx: 4174) announced the discontinuation of a Phase I/II trial for its...